Targeting antibody drugs to joints affected by arthritis
Official title: Localization of Antibody Drugs to Arthritic Joints via Collagen Hybridization
Funded at University of Utah · NIH-10973074 · Data updated 2026-11-12
This study is exploring a new way to deliver arthritis treatments directly to the joints that need help, which could make the medicine work better and cause fewer side effects for people with rheumatoid arthritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | August 22, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $402,086 |
| NIH project number | 1R01AR084689-01 |
| Project ID | NIH-10973074 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who are seeking more effective treatment options.
✕Less likely to help
Patients with conditions unrelated to rheumatoid arthritis or those who do not have joint involvement may not benefit from this research.
What this research studies
This research focuses on developing a new method to deliver antibody therapies specifically to joints affected by arthritis, minimizing side effects in other parts of the body. The approach involves creating specialized peptides that can bind to damaged collagen in arthritic tissues, allowing for targeted treatment. By synthesizing new structures and testing their effectiveness, the research aims to improve the efficacy of existing rheumatoid arthritis treatments while reducing the risk of serious side effects. Patients may benefit from a more effective and safer treatment option for their condition.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective and targeted treatment for rheumatoid arthritis, reducing side effects associated with current therapies.
How similar studies have gone: Other research has shown promise in targeted therapies for autoimmune diseases, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Yu, Michael S — University of Utah
- Study coordinator: Yu, Michael S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.